Proxima Bio develops programmable medicines that modulate protein interactions to address disease processes.
Proxima has raised $91.5M in total funding. The most recent round was Seed. The last funding was announced in January 2026.
Proxima's investors include AIX Ventures, NVentures, Modi Ventures, DCVC, Roivant Sciences.
Proxima is headquartered in New York, United States.
Proxima Bio develops programmable medicines that modulate protein interactions to address disease processes.
Proxima is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Proxima — Funding & Investors." VCBacked, January 13, 2026, https://www.vcbacked.co/company/proxima. Accessed September 13, 2026.
VCBacked. (2026). Proxima — Funding & Investors. Retrieved September 13, 2026, from https://www.vcbacked.co/company/proxima
{{cite web |title=Proxima — Funding & Investors |url=https://www.vcbacked.co/company/proxima |website=VCBacked |access-date=September 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated